Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Brukinsa
|
| gptkbp:chemicalFormula |
C22H24ClN5O2S
|
| gptkbp:clinicalTrials |
Phase 3
NCT03206970 NCT03332019 NCT03414017 NCT03787029 NCT03825731 |
| gptkbp:compatibleWith |
high
|
| gptkbp:contraindication |
severe hepatic impairment
active infection |
| gptkbp:developedBy |
BeiGene
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:endOfLife |
approximately 5-6 hours
|
| gptkbp:formulation |
oral capsule 80 mg
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zanubrutinib
|
| gptkbp:interactsWith |
anticoagulants
CYP3A4 inhibitors warfarin CYP3A4 inducers |
| gptkbp:isATypeOf |
1447018-00-2
|
| gptkbp:issuedBy |
oral capsule
|
| gptkbp:lastProduced |
2019
|
| gptkbp:mandates |
chronic lymphocytic leukemia
mantle cell lymphoma |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:Japan gptkb:USA gptkb:EU Brukinsa |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
L01XX45
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
autoimmune diseases
solid tumors leukemia treatment lymphoma treatment |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
anemia
fatigue nausea diarrhea neutropenia |
| gptkbp:targets |
Bruton's_tyrosine_kinase
|
| gptkbp:triggerType |
inhibits_BTK
|
| gptkbp:usedFor |
treatment of B-cell malignancies
|
| gptkbp:waterManagement |
feces
|